newsfilter
← Latest News
Business Wire·

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

TGTX
  • TG Therapeutics raised its full-year 2026 total global revenue guidance to approximately $1 billion from $950 million.
  • The company increased its full-year 2026 BRIUMVI U.S. net product revenue guidance to $915–920 million from $890–905 million.
  • Third-quarter 2026 total global revenue reached approximately $260 million, including $233 million in BRIUMVI U.S. net product revenue.
  • BRIUMVI U.S. net product revenue for the third quarter was $232.6 million, representing a 52% year-over-year increase.
  • TG Therapeutics repurchased approximately $100 million of common stock in Q3 2026, bringing the total repurchased amount to $300 million since inception.
  • Positive Phase 3 ENHANCE trial results demonstrated bioequivalent exposure for a single-infusion initiation regimen compared to the two-infusion regimen.
  • Phase 1 subcutaneous BRIUMVI data showed over 60% mean bioavailability relative to IV administration, supporting the quarterly dosing regimen in the Phase 3 trial.
  • Seven-year follow-up data from ULTIMATE I & II trials showed an annualized relapse rate of 0.018 with 88.3% of patients free from 24-week confirmed disability progression.
  • Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis was positive, with a registration-directed Phase 2 trial initiated.
  • A Phase 2 clinical trial evaluating BRIUMVI in treatment-resistant schizophrenia was initiated.
  • Azer-cel Phase 1 data in progressive MS showed a safety profile with no dose-limiting toxicities observed in 26 participants.
  • The company reaffirmed its full-year 2026 operating expense guidance of $450–500 million.
  • Total research and development expenses were $51.3 million for the quarter, while selling, general, administrative expenses were $80.7 million.
  • Net income for the third quarter 2026 was $55.5 million, excluding a non-recurring tax benefit from the prior year.
  • Cash, cash equivalents, and investment securities totaled $556.7 million as of September 30, 2026.
  • Top-line Phase 3 data for subcutaneous BRIUMVI is expected by year-end 2026 or early 2027.